Finally, to confirm whether ZG16B had clinical significance in breast cancer patients and investigate its effect on prognosis, we have done Kaplan–Meier plotter analysis to access the RFS survival curves in different molecular subtypes of breast cancer shown in Figure 7, and it has been observed that although most molecular subtypes except PR-positive subtype ZG16B seemingly don’t show apparent effect, ZG16B does represent a long RFS and good prognosis for all kinds of patients. This evidence concerns the gene ZG16B and breast cancer.